Neurimmune and Ono Pharmaceutical collaborate to research neurodegenerative diseases
pharmafile | January 17, 2022 | News story | Sales and Marketing |
Neurimmune AG has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical. The companies aim to focus on creating antibody drugs against new therapeutic targets in the field of neurodegenerative diseases, utilising Neurimmune’s proprietary Reverse Translational medicine (RTM) technology platform.
The companies initially signed a drug discovery collaboration agreement to identify and develop human antibodies using the RTM technology platform. As part of this new collaboration, they are focused on generating and validating human-derived monoclonal antibodies against Ono’s newly selected drug targets.
As part of the agreement, Ono will obtain exclusive rights for the worldwide development and commercialisation of antibody products resulting from the collaboration. Ono will pay Neurimmune an upfront payment, research fees, and success-based milestones on the research and development progress, in addition to royalties on product sales.
“We are excited to expand our long-term trusted partnership with Ono, a global pioneer of innovative medicines,” said Jan Grimm, CSO of Neurimmune. “The joint goal of the collaboration is to discover novel drug candidates for the treatment of neurodegenerative diseases using RTM technology.”
“We extremely appreciate Neurimmune’s RTM technology platform as an excellent antibody creation technology through our drug discovery projects,” added Toichi Takino, Senior Executive Officer / Executive Director, Discovery & Research of Ono Pharmaceutical. “Through this new collaboration, we will expand our central nervous system disease portfolio and work to deliver innovative medicines to patients with neurodegenerative diseases.”